The Angelman Syndrome Foundation advances awareness and treatment of Angelman syndrome, a neurodevelopmental disorder caused by a deficiency of the ubiquitin protein ligase UBE3A in the brain. The foundation advances this mission through education, research, and support for individuals with Angelman syndrome, their families, and other concerned parties.
As part of this mission, the foundation is accepting proposals for projects in the preclinical, translational, and clinical research areas that investigate any or all aspects of Angelman syndrome. Priority will be given to projects focused on testing new ideas about the pathogenesis and therapeutics of Angelman syndrome, translational research, and clinical research studies. Of particular interest to ASF are studies related to communication, behavioral issues, and identification of issues and treatments that impact the daily life of people with Angelman syndrome and their families.
One- or two-year grants of up to $100,000 a year will be awarded, and researchers from any country are encouraged to apply.
For complete program guidelines and application instructions, see the Angelman Syndrome Foundation's website.